Income From TAP Will Increase “Every Quarter” In 2005, Abbott Says
This article was originally published in The Pink Sheet Daily
Abbott expects the TAP joint venture with Takeda will post sequential growth every quarter in 2005 as Prevacid (lansoprazole) and Lupron (leuprolide) gain steam throughout the year
You may also be interested in...
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.
Acquisition will enable company to leverage "end-to-end" product development through post-commercialization offerings, company says. Omnicare is now in discussions with NeighborCare after raising its takeover bid to $1.55 bil.